<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35136033</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2158-3188</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Translational psychiatry</Title>
          <ISOAbbreviation>Transl Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study.</ArticleTitle>
        <Pagination>
          <StartPage>56</StartPage>
          <MedlinePgn>56</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">56</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-022-01825-0</ELocationID>
        <Abstract>
          <AbstractText>QTc interval prolongation is one of the most common antipsychotic-induced side effects which could lead to ventricular tachycardia or Torsade de Pointes, even cardiac arrest. There is very limited understanding on the genetic factors that associated with antipsychotic-induced QTc interval change. We conducted a genome-wide association study (GWAS) of antipsychotic-induced QTc interval change among patients with schizophrenia. A total of 2040 patients with schizophrenia were randomly assigned to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and first-generation antipsychotics; first-generation antipsychotics including haloperidol or perphenazine were also assigned randomly) and received 6-week antipsychotic treatment. We identified two novel loci (rs200050752 in ATAD3B and rs186507741 in SKIL) that were associated with antipsychotic-induced QTc interval change at a genome-wide significance level. The combination of polygenic risk score (PRS), based the GWAS of myocardial infarction from BioBank Japan project, and clinical data (sex, heart rate and QTc interval at baseline) could be applied to predict whether patients with schizophrenia have QTc interval prolongation (10 ms was applied as threshold, P &lt; 0.001, area under the curve [AUC] was 0.797), especially for the first episode patients (P &lt; 0.001, AUC was 0.872). We identified two loci located within genes related to mitochondrial function and cell growth and differentiation, which were both associated with schizophrenia and heart function. The combination of PRS and clinical data could predict whether patients with schizophrenia have the side effect of QTc interval prolongation, which could fundamentally guide the choice of antipsychotic in patients with schizophrenia, especially for the first-episode patients.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Zhe</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yuyanan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0003-0376-9037</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, 100096, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Liangkun</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-4223-7551</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Yundan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Tianlan</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-9785-8489</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Jining Medical University, Jining, Shandong, 272067, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Lifang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-6448-8568</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wenqiang</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-0833-246X</Identifier>
            <AffiliationInfo>
              <Affiliation>Henan Key Lab of Biological Psychiatry, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 435001, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Yongfeng</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-0358-0752</Identifier>
            <AffiliationInfo>
              <Affiliation>Henan Key Lab of Biological Psychiatry, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 435001, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Xiao</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0003-3608-6208</Identifier>
            <AffiliationInfo>
              <Affiliation>Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, 650223, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Luxian</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-3963-660X</Identifier>
            <AffiliationInfo>
              <Affiliation>Henan Key Lab of Biological Psychiatry, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, 435001, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Yunlong</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-3522-3912</Identifier>
            <AffiliationInfo>
              <Affiliation>Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, 100096, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Dai</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100871, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chinese Institute for Brain Research, Beijing, 102206, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yue</LastName>
            <ForeName>Weihua</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-1201-8465</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Mental Health, Peking University Sixth Hospital, Beijing, 100191, China. dryue@bjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 100191, China. dryue@bjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NHC Key Laboratory of Mental Health, &amp; Research Unit of Diagnosis and Treatment of Mood Cognitive Disorder (2018RU006), Chinese Academy of Medical Sciences, Beijing, 100191, China. dryue@bjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100871, China. dryue@bjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Chinese Institute for Brain Research, Beijing, 102206, China. dryue@bjmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Transl Psychiatry</MedlineTA>
        <NlmUniqueID>101562664</NlmUniqueID>
        <ISSNLinking>2158-3188</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C519737">ATAD3B protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C060615">SKIL protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.4.-</RegistryNumber>
          <NameOfSubstance UI="D000074183">ATPases Associated with Diverse Cellular Activities</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>L6UH7ZF8HC</RegistryNumber>
          <NameOfSubstance UI="D018967">Risperidone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000074183" MajorTopicYN="N">ATPases Associated with Diverse Cellular Activities</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>5</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35136033</ArticleId>
        <ArticleId IdType="pmc">PMC8825824</ArticleId>
        <ArticleId IdType="doi">10.1038/s41398-022-01825-0</ArticleId>
        <ArticleId IdType="pii">10.1038/s41398-022-01825-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388:86–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4940219</ArticleId>
            <ArticleId IdType="pubmed">26777917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007;68:e04.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17335312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozzatello P, Bellino S, Rocca P. Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. Front Psychiatry. 2019;10:67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6399388</ArticleId>
            <ArticleId IdType="pubmed">30863323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Momen NC, Plana-Ripoll O, Agerbo E, Benros ME, Børglum AD, Christensen MK, et al.  Association between Mental Disorders and Subsequent Medical Conditions. N. Engl J Med. 2020;382:1721–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7261506</ArticleId>
            <ArticleId IdType="pubmed">32348643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Therapeutic Adv Drug Saf. 2012;3:241–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4110870</ArticleId>
            <ArticleId IdType="pubmed">25083239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arzteblatt Int. 2011;108:687–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3221427</ArticleId>
            <ArticleId IdType="pubmed">22114630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al.  Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet (Lond, Engl) 2019;394:939–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6891890</ArticleId>
            <ArticleId IdType="pubmed">31303314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zai CC, Tiwari AK, Zai GC, Maes MS, Kennedy JL. New findings in pharmacogenetics of schizophrenia. Curr Opin Psychiatry. 2018;31:200–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29528898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arking DE, Pulit SL, Crotti L, van der Harst P, Munroe PB, Koopmann TT, et al.  Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nat Genet. 2014;46:826–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4124521</ArticleId>
            <ArticleId IdType="pubmed">24952745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lahrouchi N, Tadros R, Crotti L, Mizusawa Y, Postema PG, Beekman L, et al.  Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation. 2020;142:324–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7382531</ArticleId>
            <ArticleId IdType="pubmed">32429735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, Wolfgang CD, et al.  Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009;14:1024–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18521091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aberg K, Adkins DE, Liu Y, McClay JL, Bukszár J, Jia P, et al.  Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012;12:165–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3388904</ArticleId>
            <ArticleId IdType="pubmed">20921969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Yan H, Wang L, Li J, Tan L, Deng W, et al.  Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. Lancet Psychiatry. 2018;5:327–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29503163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Funk MC, Beach SR, Bostwick JR, Celano C, Hasnain M, Pandurangi A, et al.  QTc Prolongation and Psychotropic Medications. Am J Psychiatry. 2020;177:273–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32114782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1950838</ArticleId>
            <ArticleId IdType="pubmed">17701901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leucht S, Samara M, Heres S, Davis JM. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophrenia Bull. 2016;42(Suppl 1):S90–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4960429</ArticleId>
            <ArticleId IdType="pubmed">27460622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanai M, Tanaka T, Okada Y. Empirical estimation of genome-wide significance thresholds based on the 1000 Genomes Project data set. J Hum Genet. 2016;61:861–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5090169</ArticleId>
            <ArticleId IdType="pubmed">27305981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramasamy A, Trabzuni D, Guelfi S, Varghese V, Smith C, Walker R, et al.  Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat Neurosci. 2014;17:1418–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4208299</ArticleId>
            <ArticleId IdType="pubmed">25174004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6447622</ArticleId>
            <ArticleId IdType="pubmed">30944313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirokawa M, Morita H, Tajima T, Takahashi A, Ashikawa K, Miya F, et al.  A genome-wide association study identifies PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for myocardial infarction in Japanese. Eur J Hum Genet: EJHG. 2015;23:374–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4326706</ArticleId>
            <ArticleId IdType="pubmed">24916648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Federal Register. 2005; 70:61134–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16237860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasnain M, Vieweg WVR. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28:887–920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25168784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West AP, Shadel GS. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat Rev Immunol. 2017;17:363–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7289178</ArticleId>
            <ArticleId IdType="pubmed">28393922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kemp JP, Smith PM, Pyle A, Neeve VCM, Tuppen HAL, Schara U, et al.  Nuclear factors involved in mitochondrial translation cause a subgroup of combined respiratory chain deficiency. Brain: A J Neurol. 2011;134:183–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3707321</ArticleId>
            <ArticleId IdType="pubmed">21169334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schon EA, DiMauro S, Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet. 2012;13:878–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3959762</ArticleId>
            <ArticleId IdType="pubmed">23154810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shokolenko I, Venediktova N, Bochkareva A, Wilson GL, Alexeyev MF. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 2009;37:2539–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2677867</ArticleId>
            <ArticleId IdType="pubmed">19264794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan C, Duanmu X, Zeng L, Liu B, Song Z. Mitochondrial DNA: Distribution, Mutations, and Elimination. Cells. 2019;8:379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6523345</ArticleId>
            <ArticleId IdType="pubmed">31027297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kazak L, Reyes A, Holt IJ. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol. 2012;13:659–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22992591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet. 2005;6:389–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1762815</ArticleId>
            <ArticleId IdType="pubmed">15861210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemieux H, Hoppel CL. Mitochondria in the human heart. J Bioenerg Biomembranes. 2009;41:99–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19353253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wajner M, Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci Rep. 2015;36:e00281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4718505</ArticleId>
            <ArticleId IdType="pubmed">26589966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anan R, Nakagawa M, Miyata M, Higuchi I, Nakao S, Suehara M, et al.  Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation. 1995;91:955–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7850981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SR, Han J. Mitochondrial Mutations in Cardiac Disorders. Adv Exp Med Biol. 2017;982:81–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28551783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desai R, Frazier AE, Durigon R, Patel H, Jones AW, Dalla Rosa I, et al.  ATAD3 gene cluster deletions cause cerebellar dysfunction associated with altered mitochondrial DNA and cholesterol metabolism. Brain: A J Neurol. 2017;140:1595–610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5445257</ArticleId>
            <ArticleId IdType="pubmed">28549128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gunning AC, Strucinska K, Muñoz Oreja M, Parrish A, Caswell R, Stals KL, et al.  Recurrent De Novo NAHR Reciprocal Duplications in the ATAD3 Gene Cluster Cause a Neurogenetic Trait with Perturbed Cholesterol and Mitochondrial Metabolism. Am J Hum Genet. 2020;106:272–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7010973</ArticleId>
            <ArticleId IdType="pubmed">32004445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baudier J. ATAD3 proteins: brokers of a mitochondria-endoplasmic reticulum connection in mammalian cells. Biol Rev Camb Philos Soc. 2018;93:827–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28941010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tecalco-Cruz AC, Sosa-Garrocho M, Vázquez-Victorio G, Ortiz-García L, Domínguez-Hüttinger E, Macías-Silva M. Transforming growth factor-β/SMAD Target gene SKIL is negatively regulated by the transcriptional cofactor complex SNON-SMAD4. J Biol Chem. 2012;287:26764–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3411014</ArticleId>
            <ArticleId IdType="pubmed">22674574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalil H, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, et al.  Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. The. J Clin Investig. 2017;127:3770–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5617658</ArticleId>
            <ArticleId IdType="pubmed">28891814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Extramiana F, Milleron O, Elbitar S, Uccellini A, Langeois M, Spentchian M, et al.  High prevalence of ventricular repolarization abnormalities in people carrying TGFβR2 mutations. Sci Rep. 2018;8:13019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6115378</ArticleId>
            <ArticleId IdType="pubmed">30158670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira RR, Abreu R, da S, Vilar-Pereira G, Degrave W, Meuser-Batista M, et al.  TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas’ heart disease. PLoS Neglected Tropical Dis. 2019;13:e0007602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6690554</ArticleId>
            <ArticleId IdType="pubmed">31365537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JO, Park JH, Kim T, Hong SE, Lee JY, Nho KJ, et al.  A novel system-level approach using RNA-sequencing data identifies miR-30-5p and miR-142a-5p as key regulators of apoptosis in myocardial infarction. Sci Rep. 2018;8:14638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6168573</ArticleId>
            <ArticleId IdType="pubmed">30279543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kishore R, Verma SK, Mackie AR, Vaughan EE. Abramova T v, Aiko I, et al. Bone marrow progenitor cell therapy-mediated paracrine regulation of cardiac miRNA-155 modulates fibrotic response in diabetic hearts. PloS One. 2013;8:e60161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3613379</ArticleId>
            <ArticleId IdType="pubmed">23560074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Yue W, Yao Shugart Y, Li S, Cai L, Li Q, et al.  Exploring Transcription Factors-microRNAs Co-regulation Networks in Schizophrenia. Schizophrenia Bull. 2016;42:1037–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4903044</ArticleId>
            <ArticleId IdType="pubmed">26609121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yohn SE, Foster DJ, Covey DP, Moehle MS, Galbraith J, Garcia-Barrantes PM, et al.  Activation of the mGlu(1) metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M(4) muscarinic receptor allosteric modulators. Mol Psychiatry. 2020;25:2786–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6588501</ArticleId>
            <ArticleId IdType="pubmed">30116027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maas SCE, Mens MMJ, Kühnel B, van Meurs JBJ, Uitterlinden AG, Peters A, et al.  Smoking-related changes in DNA methylation and gene expression are associated with cardio-metabolic traits. Clin Epigenetics. 2020;12:157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7579899</ArticleId>
            <ArticleId IdType="pubmed">33092652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamauchi T, Kang G, Hiroi N. Heterozygosity of murine Crkl does not recapitulate behavioral dimensions of human 22q11.2 hemizygosity. Genes, Brain, Behav. 2021;20:e12719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8169709</ArticleId>
            <ArticleId IdType="pubmed">33269541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Barajas-Martínez H, Xia H, Zhang Z, Chen G, Yang B, et al.  Clinical and Functional Genetic Characterization of the Role of Cardiac Calcium Channel Variants in the Early Repolarization Syndrome. Front Cardiovascular Med. 2021;8:680819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8249565</ArticleId>
            <ArticleId IdType="pubmed">34222376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moody CL, Funk AJ, Devine E, Devore Homan RC, Boison D, McCullumsmith RE, et al.  Adenosine Kinase Expression in the Frontal Cortex in Schizophrenia. Schizophrenia Bull. 2020;46:690–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7147579</ArticleId>
            <ArticleId IdType="pubmed">32275755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park T-J, Boyd K, Curran T. Cardiovascular and craniofacial defects in Crk-null mice. Mol Cell Biol. 2006;26:6272–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1592792</ArticleId>
            <ArticleId IdType="pubmed">16880535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang D, Xue Z, Xue J, Xie D, Xiong K, Zhou H, et al.  Sinoatrial node pacemaker cells share dominant biological properties with glutamatergic neurons. Protein Cell. 2021;12:545–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8225718</ArticleId>
            <ArticleId IdType="pubmed">33548033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokotsuka-Ishida S, Nakamura M, Tomiyasu Y, Nagai M, Kato Y, Tomiyasu A, et al.  Positional cloning and comprehensive mutation analysis identified a novel KDM2B mutation in a Japanese family with minor malformations, intellectual disability, and schizophrenia. J Hum Genet. 2021;66:597–606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33402700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4112379</ArticleId>
            <ArticleId IdType="pubmed">25056061</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
